We previously identified Hop as over expressed in invasive pancreatic cancer cell lines and malignant tissues of pancreatic cancer patients, suggesting an important role for Hop in the biology of invasive pancreatic cancer. Hop is a co-chaperone protein that binds to both Hsp70/Hsp90. We hypothesised that by targeting Hop, signalling pathways modulating invasion and client protein stabilisation involving Hsp90-dependent complexes may be altered.
Introduction
Pancreatic adenocarcinoma is one of the most lethal and poorly understood human malignancies. The 5-year survival rate is between 1-4% [1] , mainly due to the lack of effective therapies. Conventional treatment used to treat pancreatic cancer such as surgery, chemotherapy, radiation or combinations of these have had very little effect on the overall survival of this disease [2] .
Hop (Hsp70/Hsp90-organising protein) or STIP1 (Stress-induced phosphoprotein 1)
mediates the association, and forms a physical complex with the molecular chaperones heat shock proteins (Hsp) Hsp70 and Hsp90 [3, 4] which is dependent on the hydrolysis of ATP and ADP/ATP exchange. Hop optimises the functional cooperation between Hsp70 and Hsp90 which requires highly co-ordinated interactions for the folding and conformational regulation of a variety of proteins [5] . The molecular chaperone complex of Hop, Hsp70 and Hsp90 is involved in the folding and maturation of key regulatory proteins involved in cell viability [6] , such as steroid hormone receptors, transcription factors and kinases (some of which are involved in cancer progression). The role of Hop in tumour progression is not fully elucidated; however, Hop has been shown to be over expressed in colonic carcinoma cells [7] and in hepatocellular carcinoma (HCC) [8] . Hop is secreted by and shown to induce proliferation in glioma tumour cells through MAPK and P13K pathways [9] . Hop has also been implicated in the controlled death process. Bredemeyer et al. [10] confirmed
Hop as a substrate of the apoptotic protease granzyme B (GzmB), as Hop was directly cleaved by GzmB in vitro and in cells undergoing GzmB-induced apoptosis.
Expression of the two cleavage fragments of Hop did not induce cell death; however, cleavage of Hop by GzmB did result in loss of Hop function in vitro.
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There is increasing evidence that heat shock proteins play an important role in the development, maintenance and progression of cancer [11] . Heat shock proteins such as, Hsp90 and Hsp70 have previously been implicated in pancreatic cancer [12, 13] .
Hsps are highly conserved molecules, which protect cells from various environmental damages, including stress and carcinogenesis [14] and are activated by the ubiquitinproteasome pathway. The covalent attachment of ubiquitin to protein regulates a number of cellular processes including responses to stress. This process is responsible for selective targeting of proteins for degradation. The induced Hsps play roles as cellular chaperones, and many modulate apoptotic pathways, particularly those involving mitochondria, conferring protection from stressful stimuli including chemotherapeutic agents [15] . Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, HER2 (ErbB2) and hypoxia inducible factor-1alpha (HIF-1alpha) [16] .
We previously profiled Hop expression in an in vitro pancreatic cancer cell line invasion model and pancreatic tumour tissue specimens [17] . In the present study, we 
Materials and methods

Cell lines
The human pancreatic cell lines Panc-1, SW1990, Capan-1, MiaPaCa-2 (ATCC, USA), HPAC (DSMZ, Germany) and BxPc-3 (ECACC, UK) were used in this study.
Clone #3 and Clone #8 were previously isolated by single cell dilution from MiaPaCa-2 in this laboratory [18] . Cells were maintained in a humidified atmosphere containing 5 % CO2 at 37 o C in Dulbecco's modified Eagles medium (DMEM)
supplemented with 5% (v/v) fetal bovine serum (Sigma-Aldrich). All cell lines were free from Mycoplasma as tested with the indirect Hoechst staining method.
Invasion assays
Invasion assays were performed as previously described [19] . Briefly, matrigel was diluted to 1 mg/ml in serum free DMEM. 100 l of matrigel was coated on each 
Immunoblotting
Whole protein was extracted from cell lysates using 1x lysis buffer (50 mM Tris-Cl, 150 mM NaCl, and 0.5% (v/v) NP-40 
siRNA transient transfections
Three pre-designed siRNAs (Ambion) were chosen for each of the protein/gene targets and transfected into cells. Hop/STIP1 siRNA targets (Ambion, #106197, #106196, and #106195). For each set of siRNA transfections carried out, a control (non-transfected) and a scrambled (SCR) (Ambion, # 17010) were used. siRNA experiments were set up using 2 l NeoFx (Ambion, AM4511), to transfect 30 nM siRNA at a cell density of 3x10 5 /ml in a 6-well plate. Transfection medium was removed after 24 hours and replaced with fresh growth medium. The transfected cells were collected at 72 and 96 hrs for immunoblotting and assayed for changes in invasion capacity at 72 hrs using the in vitro invasion assay (as previously described).
Zymography
Pancreatic cancer cells (∼70-80% confluent) were washed and replenished with serum-free DMEM for 48 hrs. Cells were then pretreated with various concentrations 
Immunoprecipitation (IP)
Protein from conditioned media was lysed in buffer (4% w/v CHAPS, 7 M urea, 2 M thiourea, 10 mM Tris-HCL, 5 mM magnesium acetate pH 8. 
Immunohistochemistry
Formalin-fixed paraffin-embedded pancreatic tumour 4-µm sections of tissue blocks were cut using a microtome, mounted onto poly-l-lysine coated slides and dried overnight at 37 o C. Slides were stored at room temperature until required. Briefly, the slides were immunohistochemically stained using primary antibodies specific for Hop/STIP1 (ab56873, Abcam). After deparaffinisation and rehydration, the slides were subjected to an antigen retrieval step consisting of 20-minute incubation in pH 9.0 buffer (Target Retrieval, Dako) in a 95°C water bath followed by cooling to room temperature. Staining was performed using an automated staining apparatus for IHC (Autostainer, Dako) according to the manufacturer's guidelines. The proper positive and negative controls were processed at the same time. The slides were counterstained with haematoxylin, dehydrated in graded alcohols and mounted (DPX, Sigma).
Scoring and interpretation was carried out by consultant pathologist NS.
Statistical Analysis
Student's t-tests (two-tailed, two-sample unequal variance) were used to analyse differences in protein expression between comparisons. A p-value ≤ 0.05*, ≤ 0.01** and ≤ 0.005*** was considered statistically significant.
Results
Hop is associated with invasive pancreatic carcinoma
We previously identified Hop/STIP1 by 2D DIGE followed by MALDI-TOF MS as 2-fold more abundant in Clone #3, a highly invasive sub-population of the human pancreatic cancer cell line MiaPaCa-2, compared to the low invasive Clone #8 [17] .
In this study, we examined constitutive Hop expression in a panel of seven human pancreatic cancer cell lines by Western immunoblot ( Fig 1A) and studied its expression with the invasive status of the cell lines (Fig 1 B&C) . All cell lines express
Hop but higher abundance of Hop was observed in the more invasive cell lines.
Hop, as a novel inducer of pancreatic cancer cell invasion
To determine whether loss of Hop affects the ability of cells to invade in vitro, we compared the ability of BxPc-3 and Panc-1 (high Hop expression) human pancreatic cancer cell lines to invade through matrigel-coated Boyden chambers post HopsiRNA transfection. As Hop-siRNA (2) and (3) were more effective at Hop knockdown (Fig 5) , we used these siRNAs for further studies. Invasion of Panc-1 cells was reduced by 50% (p=0.0005) using Hop-siRNA (2) and by 50% (p=0.003)
with Hop-siRNA (3) (Fig 2A) . Invasion of BxPc-3 transfected cells were reduced by 51% (p=0.002) using Hop-siRNA (2) and by 46% (p=0.002) in the case of HopsiRNA (3) (Fig 2B) .
Matrix metalloproteinases down regulated as a result of Hop knockdown
We further investigated how knockdown of Hop using siRNA could affect invasion.
Previously, secretion of HSP90α into the extracellular matrix surrounding tumour cells was reported to assist the activation of MMP-2 as well as contributing to tumour cell invasiveness [20, 21] . We show that Hop is found in the conditioned medium of both Panc-1 and BxPc-3 cells and therefore may possibly have an extracellular role in Hsp90 client protein activation (Fig 3A) . Inhibition of Hop by Hop-siRNA transfection reduced the expression of MMP-2 in both Panc-1 and BxPc-3 as determined by immunoblotting (Fig 3B) .
Hop co-immunoprecipitates with MMP-2
Our findings suggest that Hop may act as an extracellular protein; we confirmed that as it is not internalised, further indicating an extracellular role for Hsp90 [23] . We also show that the specific Hsp90 inhibitor, geldanamycin (17-AAG) at 0.1 µM and 1 µM blocks MMP-2 and MMP-9 [24] activation as revealed by zymography (Fig 4B) .
Invasion in the highly invasive Panc-1 and BxPc-3 cells lines was also reduced at 1 µM 17-AAG (Fig 4C & D) , proliferation and cell survival at this concentration was not effected (data not shown). (Fig 5) . These results suggest that the effect of
Role of Hop as an
Hop knockdown in pancreatic cancer may be mediated through these proteins.
Localisation of Hop membrane staining in pancreatic cancer tumours
In a small panel of pancreatic tumours we identified cytoplasmic Hop expression in areas of tumour invasion and in necrotic cells in the epithelium of paraffin embedded pancreatic tumour specimens. Cytoplasmic Hop staining was also observed in the normal ductal and acinar cells of the exocrine pancreas but at a lesser intensity compared to tumour [17] . To explore Hop as a potential target for invasive pancreatic cancer, we studied the profile of 17 pancreatic tumours, 15 invasive/metastatic pancreatic ductal adenocarcinomas (PDACs), 1 cholangiocarcinoma and 1 intraductal papillary mucinous neoplasm (IPMN). All PDACs specimens displayed cytoplasmic Hop staining (Fig 6 A-B (Fig 6D) .
Discussion
Previously, protein identification by 2D DIGE followed by MALDI-TOF MS established a 2-fold increase in Hop expression in the more invasive pancreatic cancer cell line Clone #3 compared to Clone #8 (low invasion) [17] . In this study, we investigate the role of Hop in cancer cell invasion and its potential as a therapeutic target; we firstly provide evidence that Hop expression in pancreatic cancer cell lines corresponds to their invasive abilities. We show that Hop is involved in in vitro invasion in pancreatic cancer cell lines possibly through interaction with MMP-2. To our knowledge this is the first study implicating Hop in pancreatic cancer invasion via MMP-2. Eustace et al. [16] showed that Hsp90α chaperone-complex interactions are involved in MMP-2 activity and invasiveness in the fibrosarcoma cell line, HT-1080.
Our work showed that loss of Hop after siRNA transfection reduced the invasiveness of BxPc-3 and Panc-1 cells; this decrease in invasion was mediated by a reduction in MMP-2 expression. The degradation of the extracellular matrix and connective tissue, 13 leading to tumour invasion and metastasis, is facilitated by MMPs [25] . MMPs are a family of proteinase enzymes requiring a zinc ion at their active site. MMPs are secreted extracellularly in a latent form and require activation for proteolytic activity.
They are inhibited by specific tissue inhibitors of metalloproteinases (TIMPs) (reviewed in [26] ). Gress et al. [27, 28] We cannot exclude the possibility that alteration of the Hsp90 pathway decreases invasion through interference with oncogenic signalling pathways. MET, a receptor for hepatoctye growth factor/scatter factor (HGF/SF) has been previously shown to play an important role in cancer invasion and metastasis [32] . As c-MET is a client of Hsp90, it is destabilised by the Hsp90 inhibitor, 17-AAG, which blocks reactivation of downstream signalling pathways (Akt Erk and/or STAT3) and EGFR family members [33] . Webb et al. [34] showed that geldanamycin (GA) down regulates MET expression at nanamolar concentrations, thus inhibiting HGF/SF-mediated cell motility and invasion. Another Hsp90 client protein, HER2 has been proposed to interact extracellularly with Hsp90 -activating HER2 by heterodimerisation with HER3, leading to actin remodelling and cell motility via activation of signal transduction pathways MAPK and PI3K-Akt [35, 36] .
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The localisation of Hop in pancreatic cancer tumours and its secretion by cell lines may be of importance, as shown in other studies [21, 37] , [9] . The mechanism of secreted Hop is poorly understood. Hop is secreted from fibrosarcoma cells [21] and from primary astrocyte cultures [9, 37] . Although Hop has been previously detected in the Golgi apparatus and small vesicles [38] ; no transmembrane/signal peptide is contained within the Hop sequence. Therefore secretion of Hop may be through nonclassical secretory routes or through its membrane interactions with prion proteins [39] . To exclude the possibility of Hop expression in the media due to cell lysis at a low rate, recombinant Hop could be used to mimic extracellular secreted Hop and assess its function extracellularly. There is evidence to suggest that localisation of Hop may be due to phosphorylation. Hop can be phosphorylated by cell cycle kinases, phosphorylation by cdc2 (cell division cycle 2) kinase promotes cytoplasmic retention, whereas phosphorylation by casein kinase II (CKII) promotes nuclear Hop, suggesting that Hop might move between the cytoplasm and the nucleus under certain cell cycle conditions [40, 41] . The nuclear accumulation of Hop is primarily stress regulated and CKII phosphorylation has been shown not to disrupt Hop-Hsp90 binding [36] . Longshaw et al. [42] reported that in the absence of Hop, soluble 
